{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T13:58:53Z","timestamp":1721829533503},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,5]]},"DOI":"10.7759\/cureus.28811","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T23:17:35Z","timestamp":1662419855000},"source":"Crossref","is-referenced-by-count":1,"title":["Refractory Methemoglobinemia Secondary to Topical Dapsone With Subsequent Autoimmune Hemolytic Anemia"],"prefix":"10.7759","author":[{"given":"Catharine","family":"Cantrell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Costers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandler C","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J","family":"Dudek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin K","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2344\/0003-3006(2007)54[115:TRPATO]2.0.CO;2","article-title":"The recognition, physiology, and treatment of medication-induced methemoglobinemia: a case report","volume":"54","author":"Turner MD","year":"2007","unstructured":"Turner MD, Karlis V, Glickman RS. The recognition, physiology, and treatment of medication-induced methemoglobinemia: a case report. Anesth Prog. 2007, 54:115-117. 10.2344\/0003-3006(2007)54[115:TRPATO]2.0.CO;2","journal-title":"Anesth Prog"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.114733","article-title":"Dapsone and sulfones in dermatology: overview and update","volume":"45","author":"Zhu YI","year":"2001","unstructured":"Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001, 45:420-34. 10.1067\/mjd.2001.114733","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1408272","article-title":"Methemoglobinemia as a complication of topical dapsone","volume":"372","author":"Watton C","year":"2015","unstructured":"Watton C, Smith K, Carter E. Methemoglobinemia as a complication of topical dapsone. N Engl J Med. 2015, 372:491-2. 10.1056\/NEJMc1408272","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14080","article-title":"Severe methemoglobinemia due to topical dapsone misuse in a teenage girl","volume":"37","author":"Yale S","year":"2020","unstructured":"Yale S, Stefanko N, McCarthy P, McFadden V, McCarthy J. Severe methemoglobinemia due to topical dapsone misuse in a teenage girl. Pediatr Dermatol. 2020, 37:377-8. 10.1111\/pde.14080","journal-title":"Pediatr Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/0972-5229.126089","article-title":"Acute methemoglobinemia with hemolytic anemia following bio-organic plant nutrient compound exposure: Two case reports","volume":"18","author":"Malkarnekar SB","year":"2014","unstructured":"Malkarnekar SB, Anjanappa R, Naveen L, Kiran BG. Acute methemoglobinemia with hemolytic anemia following bio-organic plant nutrient compound exposure: Two case reports. Indian J Crit Care Med. 2014, 18:115-7. 10.4103\/0972-5229.126089","journal-title":"Indian J Crit Care Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2020.e01013","article-title":"Methemoglobinemia and hemolytic anemia after COVID-19 infection without identifiable eliciting drug: a case-report","volume":"23","author":"Lopes DV","year":"2021","unstructured":"Lopes DV, Lazar Neto F, Marques LC, Lima RB, Brand\u00e3o AA. Methemoglobinemia and hemolytic anemia after COVID-19 infection without identifiable eliciting drug: a case-report. IDCases. 2021, 23:e01013. 10.1016\/j.idcr.2020.e01013","journal-title":"IDCases"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2013.11.036","article-title":"High-dose vitamin C management in dapsone-induced methemoglobinemia","volume":"32","author":"Park SY","year":"2014","unstructured":"Park SY, Lee KW, Kang TS. High-dose vitamin C management in dapsone-induced methemoglobinemia. Am J Emerg Med. 2014, 32:684.e1-3. 10.1016\/j.ajem.2013.11.036","journal-title":"Am J Emerg Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01079.x","article-title":"Complications related to dapsone use for Pneumocystis jirovecii pneumonia prophylaxis in solid organ transplant recipients","volume":"5","author":"Lee I","year":"2005","unstructured":"Lee I, Barton TD, Goral S, et al.. Complications related to dapsone use for Pneumocystis jirovecii pneumonia prophylaxis in solid organ transplant recipients. Am J Transplant. 2005, 5:2791-5. 10.1111\/j.1600-6143.2005.01079.x","journal-title":"Am J Transplant"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746080-00006","article-title":"Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris","volume":"46","author":"Thiboutot DM","year":"2007","unstructured":"Thiboutot DM, Willmer J, Sharata H, Halder R, Garrett S. Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. Clin Pharmacokinet. 2007, 46:697-712. 10.2165\/00003088-200746080-00006","journal-title":"Clin Pharmacokinet"},{"key":"ref10","article-title":"Pharmacokinetic profiles in rats after intravenous, oral, or dermal administration of dapsone","volume":"28","author":"Helton DR","year":"2000","unstructured":"Helton DR, Osborne DW, Pierson SK, Buonarati MH, Bethem RA. Pharmacokinetic profiles in rats after intravenous, oral, or dermal administration of dapsone. Drug Metab Dispos. 2000, 28:925-9.","journal-title":"Drug Metab Dispos"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2013.864394","article-title":"Very late recovery of dapsone-induced methemoglobinemia","volume":"52","author":"Wieringa A","year":"2014","unstructured":"Wieringa A, Bethlehem C, Hoogendoorn M, van der Maten J, van Roon EN. Very late recovery of dapsone-induced methemoglobinemia. Clin Toxicol. 2014, 52:80-1. 10.3109\/15563650.2013.864394","journal-title":"Clin Toxicol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3182a8f0c8","article-title":"Dapsone and body mass index in subjects with multibacillary leprosy","volume":"36","author":"Moura FM","year":"2014","unstructured":"Moura FM, Dias RM, Araujo EC, Brasil LM, Ferreira MV, Vieira JL. Dapsone and body mass index in subjects with multibacillary leprosy. Ther Drug Monit. 2014, 36:261-3. 10.1097\/FTD.0b013e3182a8f0c8","journal-title":"Ther Drug Monit"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/104693-refractory-methemoglobinemia-secondary-to-topical-dapsone-with-subsequent-autoimmune-hemolytic-anemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:41:00Z","timestamp":1707507660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/104693-refractory-methemoglobinemia-secondary-to-topical-dapsone-with-subsequent-autoimmune-hemolytic-anemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.28811","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,5]]}}}